ingly the authors could not find any difference in the number of patients who remained in sustained remission after treatment with cyclophosphamide for either eight or 12 weeks, contrary to our previous finding.2 We would like to comment on the conclusions of this study, as we find considerable differences in the treatment procedures used in their study and ours, in addition to the age differences in patients described by the authors.
Most notable is the difference in the initial treatment of nephrosis. All of our patients were treated initially according to the standard treatment protocol of the Arbeitsgemeinschaft fur Padiatrische Nephrologie (APN), that is, 60 mg/m2/day continuously for four weeks, followed by treatment on alternate days with 40 mg/m2/48 hours prednisone. In contrast, the duration of the initial treatment of patients in the study by Ueda et al was significantly longer, that is, four weeks of continuous steroid administration, followed by three to four months' treatment with tapered down prednisone dose (reduction of 5 to 10 mg/mi2 every two weeks). Perhaps the important differences may relate to the criteria for steroid dependence and the age of the patients studied. The criteria for steroid dependence they adopted is somewhat different from ours as they included the patients other than those relapsed while receiving steroids or within 14 days after stopping steroids ('fast' relapser). Such patients could be more responsive to cyclophosphamide than those with 'fast' relapse. In addition, the most striking difference is the age at which cyclophosphamide was instituted. The age at entry into the study of their patients treated for 12 weeks, who had higher relapse free rate, is higher than that of those treated for eight weeks and of our patients with relapse, but is similar to that of our patients without relapse. Cyclophosphamide appears more effective in older patients than in the younger,2 thus the distribution of the age at entry should be strictly the same in a comparative trial of such a drug. Finally, I am sure that Oemar and Brodehl would agree with me that their data must be interpreted with caution because of the retrospective nature of their study and the small number of patients in their study group. Thus in their study if the only two patients treated for 12 weeks relapsed, the differences in the efficacy of the two regimens would be insignificant.
In summary, if the data including the total time off steroids, the number of the patients without 'fast relapse' before cyclophosphamide, the age at entry into the study of patients with and without relapse, and the recent outcome after the completion of their study are available, the discrepancy between their and our results could be more clarified. We believe that the two regimens have an equivalent efficacy when a patient selection is carefully performed as described above. 
